Nasal Microbiome in COVID-19: A Potential Role of Corynebacterium in Anosmia.


Journal

Current microbiology
ISSN: 1432-0991
Titre abrégé: Curr Microbiol
Pays: United States
ID NLM: 7808448

Informations de publication

Date de publication:
30 Dec 2022
Historique:
received: 06 07 2022
accepted: 31 10 2022
entrez: 30 12 2022
pubmed: 31 12 2022
medline: 4 1 2023
Statut: epublish

Résumé

The evolution and the development of the symptoms of Coronavirus disease 19 (COVID-19) are due to different factors, where the microbiome plays a relevant role. The possible relationships between the gut, lung, nasopharyngeal, and oral microbiome with COVID-19 have been investigated. We analyzed the nasal microbiome of both positive and negative SARS-CoV-2 individuals, showing differences in terms of bacterial composition in this niche of respiratory tract. The microbiota solution A (Arrow Diagnostics) was used to cover the hypervariable V1-V3 regions of the bacterial 16S rRNA gene. MicrobAT Suite and MicrobiomeAnalyst program were used to identify the operational taxonomic units (OTUs) and to perform the statistical analysis, respectively. The main taxa identified in nasal microbiome of COVID-19 patients and in Healthy Control subjects belonged to three distinct phyla: Proteobacteria (HC = 14%, Cov19 = 35.8%), Firmicutes (HC = 28.8%, Cov19 = 30.6%), and Actinobacteria (HC = 56.7%, Cov19 = 14.4%) with a relative abundance > 1% in all groups. A significant reduction of Actinobacteria in Cov19 group compared to controls (P < 0.001, FDR = 0.01) was found. The significant reduction of Actinobacteria was identified in all taxonomic levels down to the genus (P < 0.01) using the ANOVA test. Indeed, a significantly reduced relative abundance of Corynebacterium was found in the patients compared to healthy controls (P = 0.001). Reduced abundance of Corynebacterium has been widely associated with anosmia, a common symptom of COVID-19 as suffered from our patients. Contrastingly, the Corynebacterium genus was highly represented in the nasal mucosa of healthy subjects. Further investigations on larger cohorts are necessary to establish functional relationships between nasal microbiota content and clinical features of COVID-19.

Identifiants

pubmed: 36583787
doi: 10.1007/s00284-022-03106-x
pii: 10.1007/s00284-022-03106-x
pmc: PMC9802018
doi:

Substances chimiques

RNA, Ribosomal, 16S 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

53

Subventions

Organisme : Regione Campania
ID : Task Force COVID-19 DGR 140/17 March 2020

Informations de copyright

© 2022. The Author(s).

Références

Front Microbiol. 2020 Jun 05;11:1302
pubmed: 32582134
Int J Environ Res Public Health. 2021 Feb 23;18(4):
pubmed: 33672177
Front Microbiol. 2017 Nov 29;8:2372
pubmed: 29238339
Viruses. 2021 Jan 29;13(2):
pubmed: 33572857
Front Microbiol. 2020 Jul 31;11:1840
pubmed: 32849438
Int J Mol Sci. 2021 Oct 04;22(19):
pubmed: 34639088
Healthcare (Basel). 2020 Jul 17;8(3):
pubmed: 32708986
Microorganisms. 2020 Mar 29;8(4):
pubmed: 32235377
Am J Respir Crit Care Med. 2021 Dec 15;204(12):1379-1390
pubmed: 34534435
Food Res Int. 2020 Oct;136:109577
pubmed: 32846611
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Diagnostics (Basel). 2021 Feb 12;11(2):
pubmed: 33673182
Microbiome. 2014 Aug 11;2:27
pubmed: 25143824
J Microbiol. 2021 Oct;59(10):941-948
pubmed: 34382150
Nat Microbiol. 2021 Oct;6(10):1217-1218
pubmed: 34580441
Hum Microb J. 2020 Aug;17:100073
pubmed: 32835135
Front Cell Infect Microbiol. 2022 Jan 24;11:781968
pubmed: 35141167
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Exp Mol Pathol. 2020 Feb;112:104331
pubmed: 31705881
Front Genet. 2020 Aug 04;11:872
pubmed: 32849840
Sci Rep. 2018 Jan 22;8(1):1296
pubmed: 29358754
Clin Chem Lab Med. 2020 Feb 25;58(3):340-349
pubmed: 31494628
Eur Rev Med Pharmacol Sci. 2020 Oct;24(20):10853-10859
pubmed: 33155247
Curr Opin Virol. 2021 Aug;49:21-26
pubmed: 34000641
Epidemiol Infect. 2020 Oct 26;148:e262
pubmed: 33100263
BMC Biol. 2019 Nov 7;17(1):87
pubmed: 31699101
Mucosal Immunol. 2021 Mar;14(2):305-316
pubmed: 33244161
Genomics Proteomics Bioinformatics. 2021 Oct;19(5):679-688
pubmed: 34560321
Sci Rep. 2020 Oct 2;10(1):16422
pubmed: 33009469
Microorganisms. 2020 Nov 17;8(11):
pubmed: 33213098
ACS Chem Neurosci. 2021 Oct 20;12(20):3795-3805
pubmed: 34609841
Front Cell Infect Microbiol. 2021 Feb 15;11:625581
pubmed: 33659220
Biol Proced Online. 2020 Jul 25;22:18
pubmed: 32728349

Auteurs

Carmela Nardelli (C)

Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy.
CEINGE Biotecnologie Avanzate S.C.a R.L., Naples, Italy.
Task Force On Microbiome Studies, University of Naples Federico II, Naples, Italy.

Giovanni Luca Scaglione (GL)

CEINGE Biotecnologie Avanzate S.C.a R.L., Naples, Italy.
Istituto Dermopatico Dell'Immacolata IDI-IRCSS, Rome, Italy.

Domenico Testa (D)

Department of Otorhinolaryngology, Luigi Vanvitelli University of Naples, Naples, Italy.

Mario Setaro (M)

CEINGE Biotecnologie Avanzate S.C.a R.L., Naples, Italy.

Filippo Russo (F)

Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy.
CEINGE Biotecnologie Avanzate S.C.a R.L., Naples, Italy.

Carmela Di Domenico (C)

CEINGE Biotecnologie Avanzate S.C.a R.L., Naples, Italy.

Lidia Atripaldi (L)

Clinical Biochemistry Unit, AORN Ospedale Dei Colli, Naples, Italy.

Massimo Zollo (M)

Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy.
CEINGE Biotecnologie Avanzate S.C.a R.L., Naples, Italy.

Federica Corrado (F)

Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Naples, Italy.

Paola Salvatore (P)

Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy.
CEINGE Biotecnologie Avanzate S.C.a R.L., Naples, Italy.

Biagio Pinchera (B)

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Ivan Gentile (I)

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Ettore Capoluongo (E)

Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy. ettore.capoluongo@aoec.it.
Department of Clinical Pathology and Genomics, Azienda Ospedaliera Per L'Emergenza Cannizzaro, Catania, Italy. ettore.capoluongo@aoec.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH